Swedencare Ab · OMXSTO:SECARE
Swedencare Ab — Q2 2021 Earnings Presentation
16 slides from Swedencare Ab's earnings presentation, Jul 1, 2021
Slide 1: Half-Year Report April – June 2021 Presentation
HALF-YEAR REPORT April – Juni 2021 Presentation CEO Håkan Lagerberg CFO Jenny Graflind
Slide 2: Q2 2021 Highlights
Q2 2021 Highlights Fast synergies and opening of veterinary clinics gave a record boost in Q2 Strong Growth +400% & organic growth +45%, improved profitability Strong recovery in Vet & Pet channel Strong growth in all markets and product groups – Several revenue records in group New ProDen PlaqueOff
Slide 3: Integration and other Projects
Integration and other Projects • Launch of Topicals/dermatology products in Pet Retail channel in USA • Production of dermatology products in Ireland getting closer • Move of Holden2 warehouse – larger, more effective with other group companies • Animal Pharm to Amazon and Chewy and Pet MD on Amazon
Slide 4: Key Performance Indicators Q2 2021
Key Performance Indicators Q2 2021
Slide 5: Key Performance Indicators H1 2021
Key Performance Indicators H1 2021
Slide 6: Sales per region Q2
Sales per region Q2 Q2 2021 Q2 2020
Slide 7: Sales per product category Q2
Sales per product category Q2 Q2 2021 Q2 2020
Slide 8: Sales per brand Q2
Sales per brand Q2 ANIMAL pharmaceuticals nutravet Reece €=) GEM seus ste Aen wowmuy STOMAX* GLUCOSAMIN VetWELL PRIVATE/CO LABEL we : Pet MD PlaqueOff
Slide 9: Rolling 4 Quarters
Rolling 4 Quarters 415 000 365 000 #1135 433) 315 000 124 000 265 000 104 000 215 000 84 000 165 000 64 000 115 000 |. 44 000 65 000 |__, 24 000 15 000 4 000 Qi Q2 QQ 24 QI Q QA 24 Qi Q2 QQ 24 QI Q2 2018 2019 2020 2021 2 SWEDENCARE
Slide 10: Acquisition of Vetio July 1st 2021
Acquisition of Vetio July 1st 2021 • North American premiere CDMO in Animal Health • Vetio North - Veterinary drug development and manufacturing, solid dose and non-sterile liquids • Vetio South – Development and manufacturing of OTC dermatology liquids and liquid supplements • 2020: Sales 32,3 MUSD
Slide 11: Vetio – synergies and opportunities
Vetio – synergies and opportunities • Swedencare to become top 30 leading Animal Health player with world- wide reach • Strong management and technical, production and analytical excellence • Comprehensive product capacity, incl. soft chew platform with IP • State-of-the-art product development & re
Slide 12: Financials – Proforma Swedencare TTM July 2020 – June 2021
Financials – Proforma Swedencare TTM July 2020 – June 2021 Proforma – inc. acquisitions last Swedencare 12 months Vetio Eliminations Consolidated Sales 464 185 325 -55,3 919 GM 281 91 136 507 GM% 61% 49% 42% 55% EBITDA 135 34 73 241 EBITDA% 29% 18% 22% 26%
Slide 13: Priorities 2021
Priorities 2021 Integration of acquired companies Increased Marketing Brand and Product development Distribution of full product range Handle all opportunities in various Markets and Channels Board and management will review the financial target under H2 2021
Slide 14: Q&A
Q&A 1. Vetio show lower EBITDA compared to Swedencare margin objectives (along with Holden2, while Nutravet is in the higher range). • How much will Vetio strengthen the overall margin by moving production of products in the overall range from 3rd parties into Vetio? • Are there any operational cost
Slide 15: Q&A – M&A
Q&A 4. M&A • Please explain the purchase process of Vetio, how did you find the target, what made you successful in the deal and was it an exclusive process? • Are you content in this area after the Vetio acquisition (and the other 5 done last 12 month) or do you have an appetite for more? • If so,
Slide 16: See you soon!
Live Chat starts in 5 min – See you soon!